<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656043</url>
  </required_header>
  <id_info>
    <org_study_id>XPF-005-101</org_study_id>
    <nct_id>NCT02656043</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel</brief_title>
  <official_title>A Phase 1 and 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, and Exposure of up to 12 Weeks of XPF-005 Treatment in Healthy Volunteers and Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xenon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xenon Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1/2 study enrolling 48 healthy volunteers in Phase 1 followed by 150 subjects with acne
      vulgaris in Phase 2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1/2 study enrolling 48 healthy volunteers followed by 150 subjects with acne vulgaris.
      Data from Phase 1 stage will be reviewed before progressing to Phase 2.

      Phase 1 is an open label study to determine safety, tolerability of XPF-005 topical gel and
      exposure of XEN801 (active ingredient). Four cohorts of 12 healthy volunteers will each
      receive different dose volumes of XPF-005 gel or Placebo gel on their face and back for 14 or
      21 days. Safety assessments are completed and PK samples are collected at study visits.

      Phase 2 is a randomized, double-blind, vehicle-controlled, parallel-group study to determine
      safety, tolerability, efficacy of XPF-005 topical gel and exposure of XEN801 (active
      ingredient). Approximately 150 subjects with acne vulgaris will apply XPF-005 or matching
      placebo gel on their face for 12 weeks. Safety and efficacy assessments are completed and PK
      samples are collected at study visits.

      Safety assessments include local skin tolerability assessments, vital signs, physical
      examination, 12-lead ECG, safety laboratory blood and urine and adverse event reporting.

      Efficacy assessments include acne lesion counts and Investigator's Global Assessment (IGA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in acne lesion count</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in acne lesion count</measure>
    <time_frame>Week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Investigator Global Assessment (IGA)</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>XPF-005</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment: XPF-005 Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: XPF-005 Vehicle Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XPF-005</intervention_name>
    <description>Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.</description>
    <arm_group_label>XPF-005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Vehicle gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Aged between 18 and 50, inclusive

          2. Male or female, agree to comply with contraceptive requirements

          3. Signed Informed Consent Form

          4. Clinical diagnosis of facial acne vulgaris defined as:

               -  25 to 75 inflammatory lesions,

               -  20 to 120 non-inflammatory lesions, and

               -  an IGA score of ≥3

          5. Agree to refrain from using any topical acne treatments on the face or any oral acne
             treatments. Topical acne treatment that do not have significant or measurable systemic
             absorption are permitted for treatment of the back, shoulders, and chest only

        Key Exclusion Criteria:

          1. Known sensitivity to any topical or dermal product, including alcohol

          2. Female who is breast feeding, pregnant, or planning to become pregnant

          3. Any skin condition of the face other than acne vulgaris

          4. Two or more active nodular lesions

          5. Excessive facial hair that would interfere with the evaluation of safety or with the
             diagnosis or assessment of acne vulgaris

          6. Use of tanning beds/booths, or excessive sun exposure

          7. Use of over-the-counter topical medications for treatment of acne vulgaris on the face
             within 14 days of baseline

          8. Use of systemic corticosteroids, antibiotics, anti-acne drugs, anti-inflammatory drugs
             (NSAIDs are permitted) or prescription topical retinoid use on the face within 28 days
             prior the baseline

          9. Initiation of hormonal therapy or dose change to hormonal therapy within 12 weeks
             prior to baseline.

         10. Use of androgen receptor blockers (eg, spironolactone, flutamide) within 12 weeks
             prior to baseline

         11. Use of oral retinoid (eg, isotretinoin, alitretinoin) within 12 months prior to
             baseline and vitamin A supplements &gt;10,000 units/day within 6 months prior to baseline

         12. Facial procedures (eg, microdermabrasion, chemical or laser peel) within 8 weeks prior
             to baseline

         13. Photodynamic therapy within 12 weeks prior to baseline

         14. Any other reason that would make the subject, in the opinion of the Investigator or
             Sponsor, unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Y Paul Goldberg</last_name>
    <role>Study Director</role>
    <affiliation>Xenon Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kirk Barber Research</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Skin Advancement</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stratica Medical Inc.</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical Inc.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carruthers &amp; Humphrey Clinical Research</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Dermaesthetics</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E 4M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toole Dermatology Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Médicale Nepisiguit</name>
      <address>
        <city>Bathurst</city>
        <state>New Brunswick</state>
        <zip>E2A 4Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SimcoDerm Medical and Surgical Dermatology Center</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermEdge Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research by ICLS</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Dermatology Center</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview North Dermatology Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2M 4J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Daniel Schachter Medicine Professional Corporation</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2K4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dre Angélique Gagné-Henley M.D. Inc</name>
      <address>
        <city>Saint-Jérôme</city>
        <state>Quebec</state>
        <zip>J7Z 3B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research Corporation</name>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://acne.researchstudyinfo.com/?r=10</url>
    <description>Study information and participation</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 7, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

